Posted by Michael Wonder on 28 Mar 2023
iOnctura awarded UK's MHRA Innovation Passport for entry into innovative licensing and access pathway
28 March 2023 - iOnctura today announces that the innovative medicine designation, the Innovation Passport, has been awarded for roginolisib, for the treatment of metastatic uveal melanoma by the MHRA.
Roginolisib is a first-in-class, non-ATP competitive, allosteric modulator of PI3Kd which prevents tumour proliferation and breaks immune tolerance in patients with solid and haematological tumours.
